Elevation Oncology Inc. (NASDAQ: ELEV)
$3.00
-0.0200 ( -0.66% ) 843.2K
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
Market Data
Open
$3.00
Previous close
$3.02
Volume
843.2K
Market cap
$163.64M
Day range
$2.96 - $3.27
52 week range
$0.36 - $5.83
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jun 18, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |
4 | Insider transactions | 2 | Jun 17, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |
8-k | 8K-related | 14 | Jun 14, 2024 |
4 | Insider transactions | 1 | May 17, 2024 |
10-q | Quarterly Reports | 79 | May 02, 2024 |